We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Cites Florida Drugmaker for Serious Quality Violations

FDA Cites Florida Drugmaker for Serious Quality Violations

May 19, 2017

An FDA investigation into serous quality problems at a Florida pharmaceutical company revealed a litany of unsound practices in the manufacture of experimental drugs.

FDA investigators said the quality control unit at Sancilio and Company in Riviera Beach, Fla., neglected to investigate product stability failures for finished drugs currently in clinical trial and registration batches meant to support the company’s NDAs and INDs, according to the Form 483 issued Jan. 20 and recently released by the FDA.

The facility failed to thoroughly review “any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has been already distributed,” the investigators wrote.

Sancilio develops drugs using proprietary lipid technology as a delivery system for APIs, vitamins and hormones. In addition to on-market generic fluoride and vitamin tablets, Sancilio has clinical trials underway for drugs to combat sickle cell anemia, short bowel syndrome and hypertriglyceridemia.

Ileana Barreto-Pettit, an expert investigator for the FDA, led a team of four — including two FDA chemists — who found the drugmaker had incomplete lab records, no reliable or specific test methods for some clinical drug batches, and a lack of sufficient analytical data to ensure the proper characteristics of the finished drugs.

Samples pulled from drug batches identified as placebo had inexplicable chemical anomalies and the validity of some tests were called into question because proper cleaning procedures and chain of custody protocols were not properly followed, the Form 483 said. Failed assay results were not properly recorded in the certificate of analysis and variations in sample test results were excluded from reports.

Backup data on placebo and drug batches were not secured and therefore considered potentially unreliable, with no hard copy or alternate information systems, including issues with data that investigators noted was “selectively archived.” There was no way to determine if the content of a collection of raw data were additional test files or backup files not properly stored in their designated area.

Written stability testing procedures are not followed, with the company failing to observe set timelines or follow up on inventory discrepancies.

Multiple manufacturing investigations opened in early 2016 had still not been properly investigated, reported or closed as of the inspectors’ visit to the Florida facility Jan. 1-20.

The company received two previous 483s in 2013 and 2015.

Internal Auditing Basics: A Guide for Drug and Device Manufacturers demonstrates how to build an auditing operation, including scheduling and reporting, explains regulatory requirements and discusses how to turn audit results into positive improvements.

View today's stories

Drugs Inspections and Audits

    Upcoming Events

    • 30Nov

      Medical Device Cybersecurity: Latest Regulatory Developments

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Lilly’s Claims of Mounjaro Trademark Infringement Get ITC Investigation

    • Positive Findings Generated by Element Science’s Jewel Wearable Cardiac Defibrillator

    • Biden Offers Drug Supply Chain Fixes, but Think Tank Says Government Isn’t Doing Enough

    • FDA Gives Green Light to Medtronic’s Symplicity Renal Denervation System

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing